Clinical analysis on 40 patients with chronic lymphocytic leukemia.
- Author:
Zhen-Shu XU
1
;
Jin-Yan ZHANG
;
Rong ZHAN
;
Zhi-Hong ZHENG
;
Shun-Quan WU
;
Zhi-Zhe CHEN
Author Information
1. Department of Hematology, Union Hospital of Fujian Medical University, Fuzhou, Fujian Province, China.
- Publication Type:Journal Article
- MeSH:
ADP-ribosyl Cyclase 1;
metabolism;
Adult;
Aged;
Aged, 80 and over;
Female;
Flow Cytometry;
Humans;
Immunoglobulin Variable Region;
genetics;
Leukemia, Lymphocytic, Chronic, B-Cell;
genetics;
metabolism;
Male;
Middle Aged;
Mutation;
Retrospective Studies;
ZAP-70 Protein-Tyrosine Kinase;
metabolism
- From:
Journal of Experimental Hematology
2012;20(3):583-586
- CountryChina
- Language:Chinese
-
Abstract:
This study was aimed to analyze the clinical and laboratorial characteristics of patients with chronic lymphocytic leukemia (CLL), as well as their relationship with outcomes of patients. The clinical and laboratorial data of 40 CLL patients admitted from 2004 to 2010 in our hospital were analyzed retrospectively. The results indicated that the most of CLL attacked the elderly male patients with median age 66 (from 42 to 80). Flow cytometric analysis showed that 25 cases were positive for typical immunophenotype of CLL. On the other hand, all the patients clearly expressed CD19 and CD5, 7 cases (17.5%) and 14 cases (35%) were positive for the expression of CD38 and Zap70 respectively. 8 cases harbored a mutated immunoglobulin heavy-chain (VH) gene, among them 4 cases belong to VH3 family. Interphase FISH analysis showed that P53 deletion, RB1 deletion, trisomy 12 and normal chromosome were detected in 6, 3, 1, and 5 cases, respectively. The median PFS in 31 patients received treatment of fludarabine based chemotherapy was 48 months (95%CI: 39 - 57 months), among them 27 cases (87.1%) achieved CR + PR. While PFS was 14 months (95%CI: 10 - 18 months, P < 0.001) in 9 patients received other treatment regimen, out of them only 3 cases (33.3%) achieved CR + PR. Patients with normal level of serum β2-microglobulin at diagnosis showed significantly higher overall survival (78%, 95%CI: 69% - 87%) in 36 months than those with abnormal level of serum β2-microglobulin (47%, 95%CI: 35% - 59%, P = 0.004). Significant difference in the rate of CR + PR was noted in the Zap70 positive group (50%) and in negative group (88.5%, P = 0.006). All of 8 patients with IgVH mutation displayed CR after treatment, while 4 cases (66.7%) archived CR among 6 patients without IgVH mutation. It is concluded that CLL is characterized by high heterogeneity in both clinical features and molecular markers, which are associated with prediction of outcomes for patients. The treatment with fludarabine-based chemotherapy results in a major benefit and long survival for patients with CLL.
